Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.955 USD | -1.76% | +1.54% | -33.78% |
Mar. 25 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
Mar. 25 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
Financials (USD)
Sales 2024 * | 265M | Sales 2025 * | 406M | Capitalization | 377M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | 60M | EV / Sales 2024 * | 1.42 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.93 x |
P/E ratio 2024 * |
-4.93
x | P/E ratio 2025 * |
10.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | -6.57% | ||
1 week | +6.42% | ||
Current month | -25.75% | ||
1 month | -24.05% | ||
3 months | -4.33% | ||
6 months | +160.95% | ||
Current year | -33.44% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 237 M€ | +1.04% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.98 | -0.50% | 869 271 |
24-04-25 | 1.99 | -6.57% | 5,147,052 |
24-04-24 | 2.13 | +1.91% | 5,684,029 |
24-04-23 | 2.09 | +9.42% | 4,946,560 |
24-04-22 | 1.91 | -2.05% | 4,791,912 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.44% | 377M | |
+24.71% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.51% | 233B | |
+5.67% | 201B | |
-10.18% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- ESPR Stock